Recombineering: Genetic Engineering in Escherichia coli Using Homologous Recombination
Current Protocols · 2023
DOI: 10.1002/cpz1.656 ↗Kurz gefasst
Fachartikel in der Zeitschrift Current Protocols, 2023. Verfasst von Lynn C Thomason und 3 weiteren Autor:innen. Beteiligte Einrichtung: Molecular Control and Genetics Section, RNA Biology Laboratory, National Cancer Institute at Frederick, National Institutes of Health, Frederick, Mar…. Hauptthemen laut MEDLINE: Escherichia coli, Homologous Recombination. Die Arbeit wurde bisher 35-mal zitiert (Crossref) und nennt 97 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS, Intramural NIH HHS, NIH HHS.
Abstract (Originalsprache)
The bacterial chromosome and bacterial plasmids can be engineered in vivo by homologous recombination using either PCR products or synthetic double‐stranded DNA (dsDNA) or single‐stranded DNA as substrates. Multiple linear dsDNA molecules can be assembled into an intact plasmid. The technology of recombineering is possible because bacteriophage‐encoded recombination proteins efficiently recombine sequences with homologies as short as 35 to 50 bases. Recombineering allows DNA sequences to be inserted or deleted without regard to the location of restriction sites and can also be used in combination with CRISPR/Cas targeting systems. © 2023 Wiley Periodicals LLC. This article has been contributed to by U.S. Government employees and their work is in the public domain in the USA. This article was corrected on 12 November 2024. See the end of the full text for details. Basic Protocol : Making electrocompetent cells and transforming with linear DNA Support Protocol 1 : Selection/counter‐selections for genome engineering Support Protocol 2 : Creating and screening for oligo recombinants by PCR Support Protocol 3 : Other methods of screening for unselected recombinants Support Protocol 4 : Curing recombineering plasmids containing a temperature‐sensitive replication function Support Protocol 5 : Removal of the prophage by recombineering Alternate Protocol 1 : Using CRISPR/Cas9 as a counter‐selection following recombineering Alternate Protocol 2 : Assembly of linear dsDNA fragments into functional plasmids Alternate Protocol 3 : Retrieval of alleles onto a plasmid by gap repair Alternate Protocol 4 : Modifying multicopy plasmids with recombineering Support Protocol 6 : Screening for unselected plasmid recombinants Alternate Protocol 5 : Recombineering with an intact λ prophage Alternate Protocol 6 : Targeting an infecting λ phage with the defective prophage strains
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Molecular Control and Genetics Section, RNA Biology Laboratory, National Cancer Institute at Frederick, National Institutes of Health, Frederick, Maryland.
- formerly with Molecular Control and Genetics Section, RNA Biology Laboratory, National Cancer Institute at Frederick, National Institutes of Health, Frederick, Maryland.
- Armata Pharmaceuticals, Marina del Rey, California.
- Emeritus, Molecular Control and Genetics Section, RNA Biology Laboratory, National Cancer Institute at Frederick, National Institutes of Health, Frederick, Maryland.
Förderung
- NCI NIH HHS
- Intramural NIH HHS
- NIH HHS
- National Cancer Institute
- National Institutes of Health
Zitieren
APA
Thomason, L. C., Costantino, N., Li, X., & Court, D. L. (2023). Recombineering: Genetic Engineering in Escherichia coli Using Homologous Recombination. Current Protocols. https://doi.org/10.1002/cpz1.656
Vancouver
Thomason LC, Costantino N, Li X, Court DL. Recombineering: Genetic Engineering in Escherichia coli Using Homologous Recombination. Current Protocols. 2023. doi:10.1002/cpz1.656
BibTeX
@article{Thomason2023,
author = {Thomason, Lynn C and Costantino, Nina and Li, Xintian and Court, Donald L},
title = {Recombineering: Genetic Engineering in Escherichia coli Using Homologous Recombination},
journal = {Current Protocols},
year = {2023},
doi = {10.1002/cpz1.656}
}
EUVIMED